Putting the award page together from the records…
Putting the award page together from the records…
Hopo Therapeutics, Inc. received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $14.21M obligated so far for specialized medical support. It runs to 2026-12-31, or to 2029-09-30 if every option is exercised.
Key facts · data as of Oct 21, 2026
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 21, 2026.
Cite this page: SpendQuery, Award 75A50124C00062, data as of Oct 21, 2026, https://spendquery.com/award?id=CONT_AWD_75A50124C00062_7505_-NONE-_-NONE-
Hopo Therapeutics, Inc.: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys · The follow-on: recompete brief
DEVELOPMENT OF HOPO-101 AS AN MCM (MEDICAL COUNTERMEASURE) DECORPORATION AGENT FOR THE TREATMENT OF INDIVIDUALS WITH KNOWN OR SUSPECTED INTERNAL CONTAMINATION WITH RADIONUCLIDES (THE ?MCM INDICATION?) AND/OR TOXIC HEAVY METALS OF INTEREST FOR COMMERC
Up for re-bid: ends 2026-12-31. Recompete brief →
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
5 actions since 2024-09-27. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-04-27 | P00004 | Funding only | $4.84M | THE PURPOSE OF THIS MODIFICATION IS TO: 1. PROVIDE ADDITIONAL FUNDING FOR CLIN 0001 IN THE AMOUNT OF $4,839,729.00. 2. EXTEND CLIN 0001 PERIOD OF PERFORMANCE TO 31 DEC 2026. 3. UPDATE SOW TO REVISION V20MAR2026. |
| 2026-02-25 | P00003 | Administrative change | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1. EXTEND THE BASE PERIOD, CLIN 0001, AT NO ADDITIONAL COST THROUGH 31 MAY 2026. 2. INCLUDE PROVISIONAL INDIRECT AND FRINGE RATES. |
| 2025-12-29 | P00002 | Administrative change | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1. EXTEND THE BASE PERIOD, CLIN 0001, AT NO ADDITIONAL COST THROUGH 28 FEBRUARY 2026. |
| 2025-11-05 | P00001 | Administrative change | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: 1. UPDATE SOW 2. ADD ALTERNATE COR |
| 2024-09-27 | 0 | $9.37M | DEVELOPMENT OF HOPO-101 AS AN MCM (MEDICAL COUNTERMEASURE) DECORPORATION AGENT FOR THE TREATMENT OF INDIVIDUALS WITH KNOWN OR SUSPECTED INTERNAL CONTAMINATION WITH RADIONUCLIDES (THE ?MCM INDICATION?) AND/OR TOXIC HEAVY METALS OF INTEREST FOR COMMERC |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-21). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗